Episode 221 : Update on COVID drugs
The main focus of the next few episodes will be to get an update on antiviral (and other anti-COVID) drugs. Today, I will discuss the latest on Molnupiravir and Paxlovid.
Ep 221-11 is a reassuring paper from California, confirming the reduced severity of omicron.
Molnupiravir (and Favipiravir)
Mechanism of action : The active 5′-triphosphate serves as a competitive substrate for SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), and once incorporated into nascent viral RNA, induces an antiviral effect via accumulation of mutations that increase with each viral replication cycle.
Ep 221-1: W Fisher Sc Transl Med Dec 2021: Important phase 2a study in 200 outpatients non-vaccinated and within 96 H of diagnosis.
Patients were randomized 3:1 to molnupiravir (400 or 800 mg) or placebo, orally 2 X daily for 5 days:
- Primary endpoint = time to viral RNA clearance in the 800 mg molnupiravir group (median 14 days) compared to the placebo group (median 15 days) (log rank pvalue= 0.013).
- By study end (4 weeks): 92.5% of participants receiving 800 mg molnupiravir achieved viral RNA clearance compared with 80.3% of placebo recipients
- Secondary endpoint = recovery of infectious virus
- At day 3: 1.9% of the 800 mg molnupiravir group had infectious virus compared with 16.7% of placebo group.
- At day, infectious virus was not isolated from any participants receiving 400 or 800 mg molnupiravir compared with 11.1% of placebo recipients.
So clear antiviral effect
Ep 221-2: Bernal NEJM Dec 2021: Phase 3 in 1400 outpatients unvaccinated adults with mild-to-moderate, within 5 days of laboratory-confirmed Covid-19 and at least one risk factor for severe Covid-19 illness: 800 mg Molnupiravir or placebo during 5 days.
- Risk of hospitalization or death in patients after randominsation through day 29 was lower with molnupiravir [6.9 3%] than with placebo [9.7 %].
- One death was reported in the molnupiravir group and 9 were reported in the placebo group through day 29.
Clinical benefit, but only 30% relative risk reduction of COVID-19 related hospitalization, with rather wide 95% confidence intervals (relative risk [RR] 0.69; 95% CI: 0.49–1.00)
Ep 221-3: FDA votes 13 versus 10 for emergency use authorization for the treatment of mild-moderate COVID-19 in adult patients who are within 5 days of symptom onset and are at high risk of severe COVID-19, including hospitalization or death
- Most Committee members expressed concerns over the mutagenicity of molnupiravir on the viral genome, particularly in the spike gene.
- There were specific concerns over prolonged viral replication in immunocompromised individuals.
- Some Committee members stated they would not recommend molnupiravir in pregnant individuals (risk of mutagenicity).
- Unclear efficacy against the Delta and omicron variant,
Committee members agreed there is a need for additional safety data, as well as further studies in the vaccinated and immunocompromised.
Episode 221-4: FDA letter to MSD on indications and limitations
Molnupiravir may only be used for the treatment of mild-to-moderate COVID-19 in adults:
- With positive results of direct SARS-CoV-2 viral testing, and
- Who are at high-risk for progression to severe COVID, including hospitalization or death, and
- For whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate.
Limitations on Authorized Use
• Not in patients who are less than 18 years of age.
• Not for initiation of treatment in patients requiring hospitalization due to COVID. Benefit of treatment with molnupiravir has not been observed in subjects when treatment was initiated after hospitalization due to COVID-19.
• Not for use for longer than 5 consecutive days.
• Not for use as pre-exposure or as post-exposure prophylaxis of COVID-19.
Ep 221-5: Phase 2 a trial on Favipiravir in asymptomatic or uncomplicated patients with COVID-19
Within 72 hours with 1800 mg BID Day 1, 800mg BID Days 2-10
No difference in time to viral shedding cessation or time to symptom resolution by treatment arm.
Mechanism: Paxlovid is a combination of:
- PF-07,321,332, also called Nirmatrelvir, an oral covalent 3CL protease inhibitor of SARS-CoV-2
- Ritonavir, an inhibitor of HIV-1 and HIV-2 protease. Ritonavir is here as an inhibitor of liver enzymes cytochrome P450 3A and CYP2D6, thus inhibiting the metabolism of PF-07,321,332 and allowing the administration of a lower dose of the substance.
Ep 221-6: DR Owen: preclinical data on PF-07,331,332
- Is a pan-corona inhibitor
- Does not inhibit human proteases:
- Active in a mouse model of SARS-CoV-2
- Achieved oral plasma concentrations exceeding the in vitro antiviral cell potency and was safe, in a phase I clinical trial in healthy human participants.
Ep 221-7: Mahase comments in BMJ on phase 3 trial (not published):
1,219 high-risk patients who had recently been infected
Treated within 3 days
- 0.8% of Paxlovid were hospitalised, compared with 7% of placebo
- No deaths with Paxlovid vs 7 in placebo group
Treated within 5 days of symptoms appearing,
- 1% given Paxlovid vs 6.7 of pleco’s in hospital
- No deaths with Paxlovid vs 10 in placebo.
Patients in the trial, which has not yet been published or verified, were elderly or had an underlying health condition which put them at higher risk of serious illness from Covid. They all had mild to moderate symptoms of coronavirus
Ep 221-8: FDA has authorized Paxlovid for use by adults and children over 12 years who have tested positive for SARS-CoV-2 and are at high risk of developing severe symptoms.
Pfizer is also continuing clinical trials for use
- on COVID-19 patients at standard risk of developing severe disease
- and, prophylactically, for people who had contact with infected individuals.
Ep 221-9: A warning by Joseph Heskin et al in Lancet that Ritonavir, the inhibitor of various drug metabolizing liver enzymes could enhance the activity (potentially lead to toxicity) by co-administered drugs such as statins, steroids, sedative hypnotics, anticoagulants, and antiarrhythmic therapies, many of which are prescribed in older populations at the greatest risk of complications from SARS-CoV-2 infection.
Ep 221-10: Ulrich in medRxiv 4 Jan shows that PF-07,321,332, also called Nirmatrelvir, maintains activity against 6 SARS-CoV-2 VOC, including omicron.
Note on omicron
Ep 221-11: During a period with mixed Delta and Omicron variant circulation in California, SARS-CoV-2 infections with presumed Omicron variant infection were associated with substantially reduced risk of severe clinical endpoints and shorter durations of hospital stay:
- Hospitalization risk = 0.48: 0.5 % of omicron versus 1.3 % of delta
- Hospital stay was 3.4 days shorter for omicron
- ICU admission = 0.26
- Death rate = 0.09
22 May 2021 Episode 142 Focus on T cellular immunity in COVID disease and SARS-CoV-2 vaccines
> More info
21 May 2021 Episode 141 Heterologous prime-boost; new African variants and pan-Corona vaccines
> More info
16 May 2021 Episode 140 Vaccination in children; Immune and Viral persistence: delaying the second dose
> More info
12 May 2021 Episode 139 : The Indian variant B.1.617: genetics, pathogenicity and sensitivity to neutralization
> More info
8 May 2021 Episode 138 Vaccine efficacy against SA variant and controversy over SARS-CoV-2 integration
> More info
7 May 2021 Episode 137 modeling of vaccination and responses in some immunosuppressed patients
> More info